A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Opening soon Phase 2 NCT07639021
Run by Novo Nordisk A/S · for 18 and older · All sexes
What this study is about
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Who can join (things the study team will check)
✅ You may be able to join if…
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 years or above at the time of signing the informed consent.
- Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening.
- Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.
🚫 You may not be able to join if…
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
- Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus.
Where this trial is running
- Chambliss Clinical Trials, LLC, Montgomery, Alabama, United States
- FDRC, Costa Mesa, California, United States
- Los Angeles Institute for Metabolic Research, Los Angeles, California, United States
- Encore Medical Research LLC, Hollywood, Florida, United States
- South Broward Research LLC, Miramar, Florida, United States
- West Orange Endocrinology, Ocoee, Florida, United States
- Cedar-Crosse Research Center, Chicago, Illinois, United States
- Great Lakes Clinical Trials, Chicago, Illinois, United States
- Midwest Inst For Clin Res, Indianapolis, Indiana, United States
- L-MARC Research Center, Louisville, Kentucky, United States
- Endo And Metab Cons, Rockville, Maryland, United States
- StudyMetrix Research LLC, City of Saint Peters, Missouri, United States
+ 13 more sites.
Who to contact
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07639021.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.